07:57 AM EDT, 09/09/2024 (MT Newswires) -- Tilray Brands ( TLRY ) said a new study examining the real-world impact of cannabinoid treatments on patients with fibromyalgia (FM) has been published in an open-access journal focused on alternative, complementary and integrative medicine.

The study, which was supported by Tilray Brands' ( TLRY ) division Tilray Medical, consisted of three patients with an average age of 52 years, and examined the effects of Tilray Dried Flower THC18 on chronic pain and other FM-associated symptoms. The study looked at the impact of cannabinoids on health outcomes, with a particular focus on pain, sleep, and quality of life.

"The findings of this study are encouraging and provide hope for fibromyalgia patients who are seeking effective treatments," Jose Tempero, Tilray's medical director, said.